Real‐world therapeutic effectiveness of lorlatinib after alectinib in Japanese patients with ALK‐positive non‐small‐cell lung cancer

Alectinib, an anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI), is the recommended first‐line treatment for ALK‐positive non‐small‐cell lung cancer (NSCLC) in Japan. Lorlatinib was approved as a subsequent therapeutic option after progression while receiving ALK TKI treatment. Howeve...

Descripción completa

Detalles Bibliográficos
Autores principales: Goto, Yasushi, Shukuya, Takehito, Murata, Ai, Kikkawa, Hironori, Emir, Birol, Wiltshire, Robin, Miura, Satoru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
ORIGINAL ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10236600/
https://www.ncbi.nlm.nih.gov/pubmed/36866958
http://dx.doi.org/10.1111/cas.15777

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10236600/
https://www.ncbi.nlm.nih.gov/pubmed/36866958
http://dx.doi.org/10.1111/cas.15777

Ejemplares similares